What's Happening?
GSK has decided to discontinue the development of camlipixant, a chronic cough drug acquired in a $2 billion deal with Bellus Health. This decision follows the review of data from the CALM-1 and CALM-2 phase 3 trials, which showed limited efficacy in treating
refractory chronic cough (RCC). The trials revealed that while camlipixant at a 50mg dose showed some reduction in cough frequency, the results were not consistent across studies, and a lower dose lacked efficacy. This outcome is a setback for GSK, which had high expectations for camlipixant as a key asset in its acquisition of Bellus Health.
Why It's Important?
The discontinuation of camlipixant's development is significant as it impacts GSK's strategic goals and financial projections. The drug was expected to contribute significantly to GSK's revenue targets, with potential peak sales of $3.4 billion. This setback may affect investor confidence and the company's market position, as it loses a potential revenue stream that was crucial to its growth strategy. The decision also highlights the challenges pharmaceutical companies face in drug development, particularly in the competitive and high-risk field of chronic cough treatments.
What's Next?
GSK will likely focus on other potential applications for camlipixant, such as its ongoing phase 2b BALANCE trial for irritable bowel syndrome, which could offer an alternative path to market. The company may also reassess its portfolio and strategic priorities to mitigate the impact of this setback. Investors and stakeholders will be keen to see how GSK navigates this challenge and whether it can identify new opportunities to drive growth and innovation in its pipeline.
